303 related articles for article (PubMed ID: 28790115)
1. MSH2 Loss in Primary Prostate Cancer.
Guedes LB; Antonarakis ES; Schweizer MT; Mirkheshti N; Almutairi F; Park JC; Glavaris S; Hicks J; Eisenberger MA; De Marzo AM; Epstein JI; Isaacs WB; Eshleman JR; Pritchard CC; Lotan TL
Clin Cancer Res; 2017 Nov; 23(22):6863-6874. PubMed ID: 28790115
[No Abstract] [Full Text] [Related]
2. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer.
Haron NH; Mohamad Hanif EA; Abdul Manaf MR; Yaakub JA; Harun R; Mohamed R; Mohamed Rose I
Asian Pac J Cancer Prev; 2019 Feb; 20(2):509-517. PubMed ID: 30803214
[TBL] [Abstract][Full Text] [Related]
4. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.
Dominguez-Valentin M; Joost P; Therkildsen C; Jonsson M; Rambech E; Nilbert M
BMC Urol; 2016 Mar; 16():15. PubMed ID: 27013479
[TBL] [Abstract][Full Text] [Related]
5. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Schweizer MT; Cheng HH; Tretiakova MS; Vakar-Lopez F; Klemfuss N; Konnick EQ; Mostaghel EA; Nelson PS; Yu EY; Montgomery B; True LD; Pritchard CC
Oncotarget; 2016 Dec; 7(50):82504-82510. PubMed ID: 27756888
[TBL] [Abstract][Full Text] [Related]
7. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.
Akbari MR; Zhang S; Cragun D; Lee JH; Coppola D; McLaughlin J; Risch HA; Rosen B; Shaw P; Sellers TA; Schildkraut J; Narod SA; Pal T
Fam Cancer; 2017 Jul; 16(3):351-355. PubMed ID: 28176205
[TBL] [Abstract][Full Text] [Related]
8. MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer.
McCoy P; Mangiola S; Macintyre G; Hutchinson R; Tran B; Pope B; Georgeson P; Hong MKH; Kurganovs N; Lunke S; Clarkson MJ; Cmero M; Kerger M; Stuchbery R; Chow K; Haviv I; Ryan A; Costello AJ; Corcoran NM; Hovens CM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1167-1180. PubMed ID: 34108644
[TBL] [Abstract][Full Text] [Related]
9. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
[TBL] [Abstract][Full Text] [Related]
10. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M; Denzinger S; Hammerschmied CG; Tannapfel A; Obermann EC; Wieland WF; Hartmann A; Stoehr R
J Mol Med (Berl); 2006 Oct; 84(10):833-41. PubMed ID: 16924473
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
[TBL] [Abstract][Full Text] [Related]
12. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.
Pritchard CC; Morrissey C; Kumar A; Zhang X; Smith C; Coleman I; Salipante SJ; Milbank J; Yu M; Grady WM; Tait JF; Corey E; Vessella RL; Walsh T; Shendure J; Nelson PS
Nat Commun; 2014 Sep; 5():4988. PubMed ID: 25255306
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.
Planck M; Ericson K; Piotrowska Z; Halvarsson B; Rambech E; Nilbert M
Cancer; 2003 Mar; 97(6):1551-7. PubMed ID: 12627520
[TBL] [Abstract][Full Text] [Related]
14. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
[TBL] [Abstract][Full Text] [Related]
15. Defects of DNA mismatch repair in human prostate cancer.
Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
Ruemmele P; Dietmaier W; Terracciano L; Tornillo L; Bataille F; Kaiser A; Wuensch PH; Heinmoeller E; Homayounfar K; Luettges J; Kloeppel G; Sessa F; Edmonston TB; Schneider-Stock R; Klinkhammer-Schalke M; Pauer A; Schick S; Hofstaedter F; Baumhoer D; Hartmann A
Am J Surg Pathol; 2009 May; 33(5):691-704. PubMed ID: 19252434
[TBL] [Abstract][Full Text] [Related]
17. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
18. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H
Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901
[No Abstract] [Full Text] [Related]
19. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population.
Kagawa M; Kawakami S; Yamamoto A; Suzuki O; Eguchi H; Okazaki Y; Akagi K; Tamaru JI; Arai T; Yamaguchi T; Ishida H
Jpn J Clin Oncol; 2021 Apr; 51(4):639-645. PubMed ID: 33244609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
